SEC Form 4 · accession 0001140361-18-014136
Asterias Biotherapeutics, Inc. · AST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael H. Mulroy
Officer — President and CEO · Director
Period of report
Mar 15, 2018
Accepted (ET)
Mar 19, 2018 · 7:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001572552
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 15, 2018 | A | 94,872 | $0.00 | A | 107,060 | D | |
| Common Stock | Mar 15, 2018 | F | 28,358 | $1.95 | D | 78,702 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF2 | $1.95 | Mar 15, 2018 | A | 200,000 | A | — | Mar 14, 2028 | Common Stock | 200,000 | 200,000 | D |
| Stock OptionsF3 | $3.70 | holding | — | — | — | — | Jun 25, 2027 | Common Stock | 800,000 | 800,000 | D |
Explanation of responses
- F1Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the grant of 94,782 shares of restricted stock, which is reported herewith on this Form 4.
- F2Subject to Mr. Mulroy's continued employment with the Company, 25% of the granted stock options vest on the first anniversary of the grant date, and the remaining 75% of the stock options in equal monthly installments over 36 months commencing after the first anniversary of the grant date. The grant date of these options was March 14, 2018. The stock options are exercisable upon vesting.
- F3Subject to Mr. Mulroy's continued employment with the Company, the stock options vest in equal monthly installments over 48 months commencing on July 31, 2017. The stock options are exercisable upon vesting.